NO952981D0 - Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin - Google Patents

Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin

Info

Publication number
NO952981D0
NO952981D0 NO952981A NO952981A NO952981D0 NO 952981 D0 NO952981 D0 NO 952981D0 NO 952981 A NO952981 A NO 952981A NO 952981 A NO952981 A NO 952981A NO 952981 D0 NO952981 D0 NO 952981D0
Authority
NO
Norway
Prior art keywords
cyclodextrin
acid
multicomponent
embedding
resolution
Prior art date
Application number
NO952981A
Other languages
English (en)
Other versions
NO952981L (no
Inventor
Paolo Chiesi
Paolo Ventura
Massimo Pasini
Joesef Szejtli
Maria Vikmon
Enrico Redenti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO952981D0 publication Critical patent/NO952981D0/no
Publication of NO952981L publication Critical patent/NO952981L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO952981A 1993-01-29 1995-07-27 Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin NO952981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI930141A IT1263831B (it) 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
PCT/EP1994/000205 WO1994016733A1 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin

Publications (2)

Publication Number Publication Date
NO952981D0 true NO952981D0 (no) 1995-07-27
NO952981L NO952981L (no) 1995-07-27

Family

ID=11364792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952981A NO952981L (no) 1993-01-29 1995-07-27 Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin

Country Status (18)

Country Link
US (1) US5855916A (no)
EP (1) EP0681481B1 (no)
JP (1) JPH08508711A (no)
KR (1) KR960700074A (no)
AT (1) ATE228013T1 (no)
AU (1) AU691115B2 (no)
BR (1) BR9406779A (no)
CA (1) CA2154874A1 (no)
CZ (1) CZ284606B6 (no)
DE (1) DE69431747D1 (no)
FI (1) FI953590A (no)
HU (1) HU218796B (no)
IL (1) IL108460A (no)
IT (1) IT1263831B (no)
NO (1) NO952981L (no)
NZ (1) NZ261115A (no)
WO (1) WO1994016733A1 (no)
ZA (1) ZA94572B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
AUPM456894A0 (en) * 1994-03-18 1994-04-14 Glyzinc Pharmaceuticals Limited Treatment for gastric disorders
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
WO1998002186A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
ES2174388T3 (es) * 1997-06-27 2002-11-01 Akzo Nobel Nv Solucion liquida de medicamento para administracion oral.
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
JP2000080123A (ja) * 1998-09-03 2000-03-21 Toagosei Co Ltd シアノアクリレート用硬化促進剤
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
US6740639B1 (en) * 2000-03-29 2004-05-25 Council Of Scientific & Industrial Research Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
WO2003052117A2 (en) * 2001-09-19 2003-06-26 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも1種の有効薬剤成分を含有する多構成要素固相
AU2003243354A1 (en) * 2002-05-31 2003-12-19 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
SI1542668T1 (sl) 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
CN1515260B (zh) * 2003-06-26 2010-05-05 沈阳药科大学 含hpcd的桂利嗪粉针剂和其固体制剂及其制备方法
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1570862A1 (en) * 2004-02-25 2005-09-07 JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Highly soluble binary cyclodextrin inclusion complexes
JP2007525502A (ja) * 2004-02-26 2007-09-06 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド コナゾール類の新規な結晶形態並びにそれらの製造および使用方法
CN1997372B (zh) * 2004-06-24 2010-06-02 西梯茜生命工学股份有限公司 包含依他康那唑的固态分散剂的制造方法及其医药组成物
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
NZ590489A (en) 2008-07-03 2013-01-25 Univ Virginia Patent Found Unit dosage of apadenoson
EP2331092B1 (en) 2008-08-21 2014-03-19 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
MX357677B (es) 2009-05-29 2018-07-19 Cydex Pharmaceuticals Inc Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
JP5803150B2 (ja) * 2011-03-02 2015-11-04 三菱瓦斯化学株式会社 ピロロキノリンキノンーシクロデキストリン包接体
ES2777939T3 (es) 2013-09-09 2020-08-06 Canimguide Therapeutics Ab Moduladores del sistema inmunitario
CA2936940C (en) * 2014-01-14 2023-07-04 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
US9896614B2 (en) 2014-11-05 2018-02-20 Halliburton Energy Services, Inc. Delayed acid breaker systems for filtercakes
AU2016229309B2 (en) 2015-03-06 2021-12-02 Canimguide Therapeutics Ab Immune system modulators and compositions
CN106539752B (zh) * 2015-09-18 2019-10-29 成都康弘药业集团股份有限公司 一种含有阿立哌唑的口服溶液及其制备方法
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
WO2021250482A1 (en) 2020-06-11 2021-12-16 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent
KR102356618B1 (ko) * 2021-11-17 2022-02-08 명지대학교 산학협력단 신규 포접복합체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS60185772A (ja) * 1984-03-05 1985-09-21 Mitsui Pharmaceut Inc 安定なカルモフ−ル−β−シクロデキストリンの包接化合物
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JP2571199B2 (ja) * 1987-11-25 1997-01-16 塩水港精糖株式会社 溶解性の高いサイクロデキストリンの製造方法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids

Also Published As

Publication number Publication date
ZA94572B (en) 1994-09-13
FI953590A (fi) 1995-09-14
KR960700074A (ko) 1996-01-19
IL108460A0 (en) 1994-04-12
BR9406779A (pt) 1996-02-06
DE69431747D1 (de) 2003-01-02
WO1994016733A1 (en) 1994-08-04
HU218796B (hu) 2000-12-28
AU691115B2 (en) 1998-05-07
US5855916A (en) 1999-01-05
HUT72500A (en) 1996-05-28
ITMI930141A0 (it) 1993-01-29
ITMI930141A1 (it) 1994-07-30
CZ284606B6 (cs) 1999-01-13
IL108460A (en) 1999-01-26
FI953590A0 (fi) 1995-07-27
CZ194395A3 (en) 1996-01-17
JPH08508711A (ja) 1996-09-17
IT1263831B (it) 1996-09-04
ATE228013T1 (de) 2002-12-15
NZ261115A (en) 1996-11-26
AU5971094A (en) 1994-08-15
EP0681481B1 (en) 2002-11-20
EP0681481A1 (en) 1995-11-15
CA2154874A1 (en) 1994-08-04
NO952981L (no) 1995-07-27
HU9502251D0 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
NO952981D0 (no) Höyopplöselige flerkomponent-innleiringskomplekser inneholdende et basisk medikament, en syre og et cyklodekstrin
NO954215D0 (no) Transdermal medikament-fremstilling
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
ATE224360T1 (de) Adamantan-derivate
DK1036058T3 (da) Adamantanderivater
ZA953206B (en) High solubility multicomponent inclusion complexes consisting of an acidic drug a cyclodextrin and a base
ATE170194T1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
NO954830L (no) Anvendelse av makrosykliske metallkomplekser som temperatursonder
ATE203772T1 (de) Markiergen
DE69215085T2 (de) Aminoacylderivate von gem-diphosphonsauren,verfahren zu deren herstellung und pharmazeutische zubereitungen,die sie enthalten
DE69215511T2 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
ECSP992952A (es) Preparados efervescentes (caso lea 32842)
UA39418A (uk) Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori
ITRM950260A0 (it) Procedimento per la gestione centralizzata ed emissione di biglietti per spettacoli e/o manifestazioni organizzati da terzi e mezzi per la sua attuazione.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application